Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBEX-PED
2023-504829-39-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in upper airway obstruction (UAO) and respiratory distress syndrome (RDS) comparing Dexamethasone phosphate with Placebo of dexamethasone (2 arms). Primary endpoint: Cumulative incidence of DRPE/OVAS within 48 hours post-extubation. Planned start Oct 2025; status: authorised.
02
Drugs
dexamethasone
03
Conditions
upper airway obstruction (UAO)respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2023-504829-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504829-39-00.